mcp 1

Anti-Mouse Rat Human CCL2 MCP-1 Antibody (2H5) 是一种来自美国仓鼠的 IgG, κ 抗体抑制剂，针对小鼠、大鼠和人体的 CCL2 MCP-1。

C24:1 3'-sulfo Galactosylceramide (d18:1 24:1(15Z))是成熟髓鞘中主要的硫酸盐类化合物。C24:1 3'-sulfo Galactosylceramide (d18:1 24:1(15Z)) 在大鼠小脑中发现活跃的髓发生鞘化反应时积累率高于C24 3'-sulfo 半乳糖甘油酰胺。C24:1 3'-sulfo Galactosylceramide (d18:1 24:1(15Z))与C 型凝集素和免疫球蛋白样受体相互作用使对LMIR5的亲和力高。C24:1 3'-sulfo Galactosylceramide (d18:1 24:1(15Z))诱导嗜碱细胞产生MCP-1，可通过增加LMIR5激活NFAT，但不能诱导肥大细胞 。C24:1 3'-sulfo Galactosylceramide (d18:1 24:1(15Z))在体外与CD1d 结合，并增加游离小鼠脾细胞的增殖。

INCB 3284 dimesylate is a selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2 (IC50: 3.7 nM). It can be used in the research of acute liver failure.

INCB 3284 是一种可口服且具有选择性和高亲和力的趋化因子受体 2 （CCR2） 拮抗剂，抑制单核细胞趋化蛋白 1 与 hCCR2 相互作用。INCB 3284 可用于研究失血性休克。

Bindarit 是单核细胞趋化蛋白MCP-1 CCL2，MCP-3 CCL7和MCP-2 CCL8的选择性抑制剂，具有抗炎作用。Bindarit 对 p65 和 p65 p50 诱导的 MCP-1 启动子激活具有特异性抑制作用，对其它测试的活化启动子没有影响。

MCP110 是 Ras 与 Raf-1 相互作用的抑制剂，可用于治疗人类肿瘤的研究。

MK-0812 Succinate 是一种选择性CCR2拮抗剂。

TAK-779 (Takeda 779) 是一种非肽类CCR5和CXCR3 拮抗剂，对CCR5的Ki 值为 1.1 nM，并选择性抑制R5 HIV-1。

NMI 8739 (n-docosahexaenoyl dopamine) 是 D2 自身受体的激动剂。 NMI 8739 减少 NO 的产生并引起 CCL-20、MCP-1 和 IL-6 释放的浓度依赖性抑制。

Licochalcone B 是从Glycyrrhiza inflate 根中提取的。它能够抑制淀粉样蛋白 β 自聚集作用 (IC50=2.16 μM) ，分解预先形成的 Aβ42原纤维，并通过螯合金属离子抑制金属诱导的 Aβ42聚集。

Berberrubine chloride (9-Berberoline Chloride) 是一种黄连素的有效代谢物，能够改善动物模型中溃疡性结肠炎的症状。

Nepetin (6-Methoxyluteolin) 是一种分离自Eupatorium ballotaefoliumHBK 中的天然类黄酮，具有有效的抗炎作用。它在 ARPE-19 细胞中能够抑制IL-6(IC50:4.43 μM) 、IL-8 (IC50:43.42 μM) 、MCP-1 (IC50:4.17 μM) 的分泌。

1V209 (TLR7 agonist T7) 是一种 Toll 样受体 7 (TLR7) 激动剂，可与各种多糖缀合，以改善其水溶性，增强功效并保持低毒性，具有抗肿瘤作用。

Talabostat (PT100, Val-boroPro) is a potent, nonselective and orally available dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 0.18 nM. Talabostat is a nonselective DPP-IV inhibitor, inhibiting DPP8 9, FAP, DPP2 and some other DASH family enzymes essentially as potently as it inhibits DPP-IV[1]. Talabostat stimulates the immune system by triggering a proinflammatory form of cell death in monocytes and macrophages known as pyroptosis. The inhibition of two serine proteases, DPP8 and DPP9, activates the proprotein form of caspase-1 independent of the inflammasome adaptor ASC[2]. Talabostat competitively inhibits the dipeptidyl peptidase (DPP) activity of FAP and CD26 DPP-IV, and there is a high-affinity interaction with the catalytic site due to the formation of a complex between Ser630 624 and the boron of talabostat[3]. Talabostat can stimulate immune responses against tumors involving both the innate and adaptive branches of the immune system. In WEHI 164 fibrosarcoma and EL4 and A20 2J lymphoma models, PT-100 causes regression and rejection of tumors. The antitumor effect appears to involve tumor-specific CTL and protective immunological memory. Talabostat treatment of WEHI 164-inoculated mice increases mRNA expression of cytokines and chemokines known to promote T-cell priming and chemoattraction of T cells and innate effector cells[3]. Talabostat treated mice show significant less fibrosis and FAP expression is reduced. Upon PT100 treatment, significant differences in the MMP-12, MIP-1α, and MCP-3 mRNA expression levels in the lungs are also observed. Treatment with PT100 in this murine model of pulmonary fibrosis has an anti-fibro-proliferative effect and increases macrophage activation[4]. [1]. Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. [2]. Okondo MC, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017 Jan;13(1):46-53. [3]. Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. [4]. Egger C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017 Aug 15;809:64-72.

BX471 (BX 471) 是可口服的非多肽 CCR1选择性拮抗剂，Ki 值为 1 nM，对其选择性是对 CCR2、CCR5 和 CXCR4 的 250 倍。

N,N-Dimethylsphingosine（N,N-二甲基鞘胺醇）是一种内源性代谢物，是一种有效的竞争性的鞘氨醇激酶（SphK）抑制剂，能够选择性地抑制鞘氨醇的磷酸化，而不影响其N-酰化。DMS在神经病理性疼痛模型中水平升高，可能通过增加 IL-1β 和 MCP-1 的释放介导机械性痛觉过敏。

Euphohelioscopin A, an activator of protein kinase C (PKC), it inhibits proliferation and induces differentiation of the myeloid leukemia cell lines THP-1 and HL-60. Euphohelioscopin A has anti-inflammary activity, it exhibits moderate inhibitory activity

CCR2 antagonist 4 hydrochloride is a specific CCR2 antagonist (IC50s: 180 nM for CCR2b). It potently inhibits MCP-1-induced chemotaxis (IC50: 24 nM).

Complement factor I，一丝氨酸蛋白酶，可与辅助因子H (FH)、补体受体1 (CR1 CD35)、C4结合蛋白 (C4BP) 或膜辅助因子蛋白 (MCP CD46) 结合，调控液相及 或细胞表面补体系统的活性。

Cantharidin imide is a PP1 2A inhibitor found in Canarthis vesicatoria. It inhibits proliferation of colorectal cancer cells, increases MCP-1, IL-6, and IL-β levels, and inhibits differentiation and resorptive activity of osteoclasts. This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.

1-Methylcyclopropene（1-MCP）是一种有效的乙烯抑制剂，能与乙烯受体不可逆地结合，阻断其结合位点。此化合物能显著提升SOD和POD的活性，并延缓软枣猕猴桃在储存期间的软化过程，从而延长果实的保质期。1-Methylcyclopropene通过减少细胞壁修饰酶的活性，进而减缓细胞壁成分（包括果胶、纤维素和半纤维素）的分解。

STAT3-IN-31 (compound K2071)，一种基于STATtic开发的STAT3和有丝分裂抑制剂，具备阻断有丝分裂进展及干扰纺锤体形成的功能。此外，它能够抑制胶质母细胞瘤细胞的迁移和肿瘤球体中细胞的增殖，诱导细胞衰老，并抑制抗Temozolomide的胶质母细胞瘤细胞生长，以及单核细胞趋化蛋白MCP-1的分泌，从而阻止炎症反应。

GPR183 antagonist-2 (化合物 32) 是一种选择性GPR183拮抗剂，水溶性好，药代动力学特性优异。该化合物能剂量依赖性地减轻胶原诱导的关节炎(CIA)小鼠模型中的爪子和关节肿胀，并显著抑制促炎细胞因子(MCP-1，MMPs 和 VEGF)的基因表达。GPR183 antagonist-2 适用于自身免疫性疾病的研究。

Lupeol acetate（乙酸羽扇醇酯）是Lupeol（羽扇醇酯）的衍生物，具有抗癌，抗炎，抗糖尿病，抗蛇毒，抗生育作用，具有口服活性。能够下调炎症细胞因子（TNF-α、IL-1β、MCP-1、COX-2、VEGF、granzyme B）从而抑制类风湿关节炎。对Hep-3B和A549细胞有细胞毒性。